Rationale, Opportunities, and Reality of Biosimilar Medications.
Publication
, Journal Article
Lyman, GH; Zon, R; Harvey, RD; Schilsky, RL
Published in: N Engl J Med
May 24, 2018
Duke Scholars
Published In
N Engl J Med
DOI
EISSN
1533-4406
Publication Date
May 24, 2018
Volume
378
Issue
21
Start / End Page
2036 / 2044
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Humans
- Health Knowledge, Attitudes, Practice
- Government Regulation
- General & Internal Medicine
- Drug Labeling
- Drug Industry
- Drug Approval
- Biosimilar Pharmaceuticals
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., Zon, R., Harvey, R. D., & Schilsky, R. L. (2018). Rationale, Opportunities, and Reality of Biosimilar Medications. N Engl J Med, 378(21), 2036–2044. https://doi.org/10.1056/NEJMhle1800125
Lyman, Gary H., Robin Zon, R Donald Harvey, and Richard L. Schilsky. “Rationale, Opportunities, and Reality of Biosimilar Medications.” N Engl J Med 378, no. 21 (May 24, 2018): 2036–44. https://doi.org/10.1056/NEJMhle1800125.
Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, Opportunities, and Reality of Biosimilar Medications. N Engl J Med. 2018 May 24;378(21):2036–44.
Lyman, Gary H., et al. “Rationale, Opportunities, and Reality of Biosimilar Medications.” N Engl J Med, vol. 378, no. 21, May 2018, pp. 2036–44. Pubmed, doi:10.1056/NEJMhle1800125.
Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, Opportunities, and Reality of Biosimilar Medications. N Engl J Med. 2018 May 24;378(21):2036–2044.
Published In
N Engl J Med
DOI
EISSN
1533-4406
Publication Date
May 24, 2018
Volume
378
Issue
21
Start / End Page
2036 / 2044
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Humans
- Health Knowledge, Attitudes, Practice
- Government Regulation
- General & Internal Medicine
- Drug Labeling
- Drug Industry
- Drug Approval
- Biosimilar Pharmaceuticals